Lexicon Highlights Sotagliflozin A1c Reductions and Renal-Independent Pilavapadin PK
LXRX•Lexicon will present pooled inTandem trial data showing consistent A1c reductions with sotagliflozin across adult Type 1 diabetes subgroups and targets an NDA resubmission in mid-2026. It will also report pilavapadin’s unchanged pharmacokinetics across renal function groups at the ADA 2026 Scientific Sessions.
1. ADA 2026 Presentations
Lexicon will present two posters on June 7 at the American Diabetes Association 2026 Scientific Sessions, detailing clinical findings for its investigational therapies sotagliflozin in Type 1 diabetes and pilavapadin in diabetic peripheral neuropathic pain.
2. Sotagliflozin Data and NDA Timeline
A pooled analysis of the inTandem phase 3 trials demonstrates consistent hemoglobin A1c reductions across key adult Type 1 diabetes subgroups, reinforcing dual SGLT1/SGLT2 inhibition benefits ahead of a planned NDA resubmission in mid-2026.
3. Pilavapadin Pharmacokinetics Findings
A Phase 1, open-label study shows pilavapadin’s pharmacokinetic profile is not influenced by renal function variation, indicating no dose adjustment is required for patients with impaired kidney function.
